A review published this month in Frontiers in Cardiovascular Medicine details the increasing understanding of cardiomyopathy linked to human immunodeficiency virus (HIV). Researchers from institutions in the United States and Nigeria collaborated on the study, which examines the molecular mechanisms, clinical presentations, diagnostic methods, and treatment options for HIV-associated cardiomyopathy.
The review, authored by Toluwalase Awoyemi of Northwestern University Feinberg School of Medicine, and a team of fourteen other researchers, highlights the growing global health concern as HIV patients live longer due to advances in treatment. This increased longevity is revealing a greater incidence of long-term cardiovascular complications, including cardiomyopathy.
Cardiomyopathy, a disease of the heart muscle, can manifest in various forms and lead to heart failure. The review investigates the specific ways HIV impacts the heart, focusing on the underlying biological processes involved. According to research published in JAMA Internal Medicine, cardiac involvement in AIDS patients has been reported in between 28% and 73% of cases.
The study emphasizes the need for improved diagnostic approaches to identify HIV-associated cardiomyopathy. Advances in cardiac imaging and immunology are contributing to a deeper understanding of the disease’s pathogenesis, as noted in a recent publication in the American Journal of Cardiology. The authors suggest that early detection and intervention are crucial for managing the condition and improving patient outcomes.
Researchers acknowledge that the prevalence of cardiovascular disease in people living with HIV remains a significant issue, despite improvements in HIV treatment. A study published by MDPI indicates that the extended lifespan of HIV patients is shifting the focus to the long-term effects of the virus on cardiovascular health. The review aims to provide clinicians and researchers with valuable insights into this complex relationship, ultimately leading to better care for individuals affected by HIV and its cardiovascular consequences.
The collaborative research team included experts from institutions such as Meharry Medical College, Kansas City University College of Medicine, Olabisi Onabanjo University Teaching Hospital, and Columbia University Mailman School of Public Health. The review does not detail specific treatment protocols, but rather focuses on understanding the disease process to inform future therapeutic strategies.
